Japanese Encephalitis Vaccines Market - Market Share, Industry Analysis with Key Companies 2024-2031

Japanese Encephalitis Vaccines Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Japanese Encephalitis (JE) Vaccines Market is segmented By Vaccine Type (Live-attenuated vaccines, Inactivated vaccines, Others) By Distribution Channel (Hospitals, Retail, Online)&nbsp;and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

<h3>Market Overview</h3>

<blockquote>
Global Japanese Encephalitis (JE) Vaccines Market reached US$ YY&nbsp;million in 2023 and is expected to reach US$ YY&nbsp;million by 2031, growing with a CAGR of YY% during the forecast period 2024-2031.
</blockquote>

Japanese encephalitis (JE) vaccines are vaccines that provide immunity against Japanese encephalitis virus (JEV), which is a mosquito-borne virus that can cause inflammation of the brain. Japanese encephalitis is primarily found in rural areas of Asia and the Western Pacific, with the highest incidence in rural parts of Southeast Asia and the Far East.

JE vaccines are integrated into national immunization programs in endemic countries where the disease burden is significant. Governments and public health authorities prioritize vaccination efforts as part of broader strategies to reduce the incidence of Japanese encephalitis and its impact on public health. Addressing Japanese encephalitis aligns with global health security initiatives aimed at preventing, detecting, and responding to infectious disease threats. Strengthening vaccination programs and disease surveillance capacities contribute to overall efforts to mitigate the spread of emerging infectious diseases.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Vaccine Type, Distribution Channel
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Growing Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Europe
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details of the report -&nbsp;<a href="https://www.datamintelligence.com/download-sample/japanese-encephalitis-vaccines-market" target="_blank">Request for sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers and Restraints</h3>

Increasing incidence of Japanese Encephalitis

The prevalence of Japanese Encephalitis virus (JEV) in endemic regions, particularly in Asia and the Western Pacific, drives the demand for JE vaccines. The high incidence of JE cases, especially during peak transmission seasons, underscores the importance of vaccination as a preventive measure. The surge in JE cases often prompts concerns among travelers visiting endemic regions.&nbsp;

Tourists, business travelers, and expatriates become more vigilant about potential health risks, including mosquito-borne diseases like JE. Travel medicine practitioners and travel advisory services emphasize the importance of JE vaccination for individuals traveling to affected areas, thereby driving demand for vaccines.&nbsp;

Also, the rising prevalence of diseases helps to accelerates the market growth. For instance, according to an article published in National Library of Medicine 2022, estimated that, there are between 30,000 and 50,000 global cases of Japanese encephalitis each year. Severe disease is estimated to occur in about one in 250 infections. Additionally, European Centre for Disease Prevention and Control (ECDC), estimated that, the overall global incidence of Japanese encephalitis is unknown, but estimates suggest that there are approximately 14 000 to 20 000 fatal cases of acute illness per year.

Market Dynamics: Restraint

High cost associated with the vaccines

High vaccine prices can pose challenges for low-income countries with limited healthcare budgets. These countries may struggle to afford the cost of JE vaccines for inclusion in national immunization programs, leading to limited accessibility for populations at risk. For instance, in countries with high JE burden such as India, affordability issues have historically hindered widespread vaccination coverage.&nbsp;

When JE vaccines are prohibitively expensive, vaccine coverage rates may suffer, leading to suboptimal protection against Japanese encephalitis. Individuals and communities may forego vaccination due to cost concerns, resulting in gaps in immunization coverage and leaving vulnerable populations at risk of infection.

<h3>Segment Analysis</h3>

The global japanese encephalitis vaccines market is segmented based on vaccine type, distribution channel and region.

The live-attenuated vaccines from the vaccine type segment accounted for approximately 62.3% of share

The rise of the live-attenuated vaccines segment for Japanese Encephalitis (JE) vaccines market can be attributed to several factors, including efficacy, ease of administration, and potential cost-effectiveness. Live-attenuated vaccines offer certain advantages over other types of vaccines, contributing to their increasing popularity.&nbsp;

For instance, the live-attenuated SA 14-14-2 vaccine has been widely used in China as part of the national immunization program since the late 1980s. This vaccine has demonstrated high efficacy and safety profiles in multiple studies and has been instrumental in reducing the burden of Japanese encephalitis in China. The successful implementation of the SA 14-14-2 vaccine in China has contributed significantly to the rise of the live-attenuated vaccines segment in the JE vaccines market.

&nbsp;Additionally, ease of administration and potential cost-effectiveness of live-attenuated vaccines make them attractive options for rapid deployment in emergency situations. Governments and international organizations often rely on live-attenuated vaccines for mass vaccination campaigns, further driving the growth of this segment in the JE vaccines market.

<h3>Geographical Analysis</h3>

Asia Pacific accounted for approximately 20.16% of the market share in 2022

The Asia Pacific region accounts for the majority of Japanese encephalitis cases globally, with countries such as India, China, Bangladesh, and Indonesia experiencing high disease burden. The prevalence of JE in these countries drives the demand for vaccines as a preventive measure against the disease.&nbsp;

For instance, according to Indian Journal of Medical Research 2022, estimated that, approximately 67,900 cases are reported every year. The case fatality rate is approximately 25%, and approximately 50 per cent of the cases reportedly suffer from permanent neuropsychiatric dysfunction. Additionally, many countries in the Asia Pacific region have implemented government-led immunization programs to control Japanese encephalitis. These programs aim to vaccinate vulnerable populations, particularly children, through routine immunization schedules.&nbsp;

For instance, countries like China, India, and Thailand have incorporated JE vaccination into their national immunization programs, contributing to increased vaccine uptake in the region. Governments and healthcare authorities have prioritized expanding vaccine coverage to reach underserved populations, including those in rural and remote areas. As a result, more individuals in the region have access to JE vaccination, driving market growth.

<h3>COVID-19 Impact Analysis</h3>

Many healthcare systems and public health agencies redirected their resources and attention towards combating COVID-19, leading to a temporary diversion of resources away from routine immunization programs, including those for JE vaccines. This redirection of resources may have impacted the implementation of vaccination campaigns and routine immunization schedules for Japanese encephalitis.&nbsp;

COVID-19-related restrictions, such as lockdowns, travel restrictions, and social distancing measures, posed challenges to the delivery of immunization services, including JE vaccination. Healthcare facilities faced disruptions in vaccine delivery, reduced clinic hours, and changes in vaccination protocols to minimize the risk of COVID-19 transmission. These disruptions could have affected vaccine coverage rates for JE and other vaccine-preventable diseases.&nbsp;

<h3>Competitive Landscape</h3>

The major global players in the market include Bharat Biotech International Limited, Valneva Austria GmbH, Sanofi, Meiji Holdings Co., Ltd., Biological E. Limited, Chengdu Institute of Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited among others.

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global japanese encephalitis vaccines market segmentation based on vaccine type, distribution channel and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of japanese encephalitis vaccines market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global japanese encephalitis vaccines market report would provide approximately 69 tables, 58 figures and 187 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Vaccine Type</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Market Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing incidence of Japanese Encephalitis</li>
				<li>Rising research and development activities focused on improving JE vaccines&nbsp;</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Restraints
		<ol>
			<li>High cost associated with the vaccines</li>
		</ol>

		<ol>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Vaccine Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Attractiveness Index, By Vaccine Type</li>
		</ol>
		</li>
		<li>Live-attenuated vaccines *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Inactivated vaccines</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospitals *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Retail&nbsp;</li>
		<li>Online</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Bharat Biotech International Limited *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Valneva Austria GmbH</li>
		<li>Sanofi</li>
		<li>Meiji Holdings Co., Ltd.</li>
		<li>Biological E. Limited</li>
		<li>Chengdu Institute of Biological Products Co., Ltd.</li>
		<li>Takeda Pharmaceutical Company Limited&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Japanese Encephalitis Vaccines Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 6 Global Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 7 Global Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 8 Global Japanese Encephalitis Vaccines Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 9 Global Japanese Encephalitis Vaccines Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 11 North America Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 12 North America Japanese Encephalitis Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 13 Asia-Pacific Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 14 Asia-Pacific Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 15 Asia-Pacific Japanese Encephalitis Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 17 Europe Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 18 Europe Japanese Encephalitis Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 19 South America Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 20 South America Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 21 South America Japanese Encephalitis Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East and Africa Japanese Encephalitis Vaccines Market Value, By Vaccine Type, 2022-2031 (US$ Million)

Table 23 Middle East and Africa Japanese Encephalitis Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Middle East and Africa Japanese Encephalitis Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Bharat Biotech International Limited: Overview

Table 26 Bharat Biotech International Limited: Product Portfolio

Table 27 Bharat Biotech International Limited: Key Developments

Table 28 Valneva Austria GmbH: Overview

Table 29 Valneva Austria GmbH: Product Portfolio

Table 30 Valneva Austria GmbH: Key Developments

Table 31 Sanofi: Overview

Table 32 Sanofi: Product Portfolio

Table 33 Sanofi: Key Developments

Table 34 Meiji Holdings Co., Ltd.: Overview

Table 35 Meiji Holdings Co., Ltd.: Product Portfolio

Table 36 Meiji Holdings Co., Ltd.: Key Developments

Table 37 Biological E. Limited: Overview

Table 38 Biological E. Limited: Product Portfolio

Table 39 Biological E. Limited: Key Developments

Table 40 Chengdu Institute of Biological Products Co., Ltd.: Overview

Table 41 Chengdu Institute of Biological Products Co., Ltd.: Product Portfolio

Table 42 Chengdu Institute of Biological Products Co., Ltd.: Key Developments

Table 43 Takeda Pharmaceutical Company Limited: Overview

Table 44 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 45 Takeda Pharmaceutical Company Limited: Key Developments

List of Figures

Figure 1 Global Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 2 Global Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 3 Global Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 4 Global Japanese Encephalitis Vaccines Market Share, By Region, 2023 &amp; 2031 (%)

Figure 5 Global Japanese Encephalitis Vaccines Market Y-o-Y Growth, By Vaccine Type, 2023-2031 (%)

Figure 6 Live-attenuated vaccines Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 7 Inactivated vaccines Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 8 Others Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 9 Global Japanese Encephalitis Vaccines Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 10 Hospitals Distribution Channel in Global Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 11 Retail Distribution Channel in Global Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 12 Online Distribution Channel in Global Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 13 Global Japanese Encephalitis Vaccines Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 14 North America Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 15 North America Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 16 North America Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 17 North America Japanese Encephalitis Vaccines Market Share, By Country, 2023 &amp; 2031 (%)

Figure 16 Asia-Pacific Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 17 Asia-Pacific Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 18 Asia-Pacific Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 19 Asia-Pacific Japanese Encephalitis Vaccines Market Share, By Country, 2023 &amp; 2031 (%)

Figure 20 Europe Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 22 Europe Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 23 Europe Japanese Encephalitis Vaccines Market Share, By Country, 2023 &amp; 2031 (%)

Figure 24 South America Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 25 South America Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 26 South America Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 27 South America Japanese Encephalitis Vaccines Market Share, By Country, 2023 &amp; 2031 (%)

Figure 28 Middle East and Africa Japanese Encephalitis Vaccines Market Value, 2022-2031 (US$ Million)

Figure 29 Middle East and Africa Japanese Encephalitis Vaccines Market Share, By Vaccine Type, 2023 &amp; 2031 (%)

Figure 30 Middle East and Africa Japanese Encephalitis Vaccines Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 31 Bharat Biotech International Limited: Financials

Figure 32 Valneva Austria GmbH: Financials

Figure 33 Sanofi: Financials

Figure 34 Meiji Holdings Co., Ltd.: Financials

Figure 35 Biological E. Limited: Financials

Figure 36 Chengdu Institute of Biological Products Co., Ltd.: Financials

Figure 37 Takeda Pharmaceutical Company Limited: Financials

Japanese Encephalitis Vaccines Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Cannabis Use Disorder Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 January 22

Starting from

Cannabis Vaporizer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 June 04

Starting from

Cannabis Seeds Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2023 October 30

Starting from